Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto

A composition and compound technology, applied in the directions of medical preparations containing active ingredients, sugar derivatives, aerosol delivery, etc.

Pending Publication Date: 2020-12-11
EMORY UNIVERSITY
View PDF33 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are serious concerns about the use of aerosol-delivered virulent strains of the VEE virus as bioweapons against warfighters

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
  • 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
  • 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Examples

Experimental program
Comparison scheme
Effect test

example 1

[1883] Conjugate preparation

[1884]Monophosphate and diphosphate prodrugs have been prepared by several groups. See Jessen et al., "Bioreversible Protection of Nucleoside Diphosphates", "Angewandte Chemie-International Edition English" 2008, 47(45), 8719-8722, The above references are hereby incorporated by reference. To prevent the cleavage of P-O-P anhydride bonds, rapidly cleaved side groups (e.g., bis-(4-acyloxybenzyl)-nucleoside diphosphate (BAB-NDP) deacylated by endogenous esterases) are utilized at the A negative charge is created on the diphosphate. See also Routledge et al., "Synthesis, Bioactivation and Anti-HIV Activity of 4-Acyloxybenzyl-bis(nucleoside-5'-yl) phosphate (nucleosid-5′-yl)Phosphates)”, “Nucleosides & Nucleotides” 1995, 14(7), 1545-1558 and Meier et al., “2′,3′-Dideoxy-2′ ,Comparative study of bis(benzyl)phosphate triesters of 3′-didehydrothymidine (d4T) and cycloSal-d4TMP-hydrolysis, mechanistic insight and anti-HIV activity ,3′-dideoxy-2′,3′-...

example 2

[1887] General procedure for base coupling

[1888] Prepare persilylation under nitrogen in a round bottom flask containing dry nucleobase (15.5 mmol), chlorotrimethylsilane (12.21 mmol) and bis(trimethylsilyl)amine (222 mmol) nucleobase. The mixture was refluxed overnight (16 hours) with stirring until all solids had dissolved. The mixture was cooled to room temperature and volatiles were removed by rotary evaporation followed by high vacuum to obtain persilylated nucleobases. This compound was used immediately in the next step.

[1889] Freshly prepared persilylated nucleobase (15.50 mmol) was dissolved in 1,2-dichloroethane (50 mL) or chlorobenzene (50 mL) with stirring under nitrogen at room temperature. A solution of β-D-ribofuranose 1,2,3,5-tetraacetate (7.75mmol) in 1,2-dichloroethane (50mL) or chlorobenzene (50mL) was added to the Stir in the mixture.

[1890] To this mixture was added SnCl dropwise via syringe 4 (11.63 mmol), and the mixture was stirred at room ...

example 3

[1892] General Cytosine Analog Conjugation

[1893] in N 2 , with N 4 - A flask of benzoyl-protected cytosine analogue (0.793 mmol) was added bis(trimethylsilyl)amine (8.45 mmol) and ammonium sulfate (0.02 mmol). The flask was heated at reflux for 2 hours, and after cooling to room temperature, the solvent was removed in vacuo and further dried under high vacuum for 1 hour. The residue was dissolved in dry chlorobenzene (10 ml), and β-D- or β-L-ribofuranose 1,2,3,5-tetraacetate (0.53 mmol) was added. Then, add SnCl dropwise 4 (0.27ml, 2.3mmol). After stirring at room temperature for 1 hour, it was heated to 60° C. overnight. After cooling to 0 °C, solid sodium bicarbonate (0.85 g) was added followed by EtOAc (5 mL). It was allowed to stir for 15 minutes, and then water (0.5 mL) was added slowly. Insoluble material was filtered off and washed with more EtOAc (2.5 mL). The filtrate was washed once with water, once with brine, and dried (Na 2 SO 4 ) and concentrated in ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can include tongaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infections.

Description

[0001] Cross References to Related Applications [0002] This application claims "4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO" filed on March 7, 2018 and entitled "4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO" priority of U.S. Provisional Patent Application No. 62 / 639,725, the entire disclosure of which is incorporated herein by reference. [0003] Statement of Government Support [0004] This invention was made with Government support under Grant Nos. HDTRA1-13-C-0072 and HDTRA1-15-C-0075 awarded by the Defense Threat Reduction Agency and Grant No. HHSN272201500008C awarded by the National Institute of Allergy and Infectious Diseases. The government has certain rights in this invention. technical field [0005] The present disclosure relates to halogen-containing nucleotide and nucleoside therapeutic compositions and their related uses. In certain embodiments, the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D307/12A61K31/505C07D239/10C07D405/04
CPCA61K31/505C07H19/06C07H19/067C07H19/20C07H19/207A61P31/12Y02A50/30A61K2300/00A61K31/7072A61P31/14A61K9/008A61P31/16A61K31/7068A61K9/124
Inventor 乔治·R·佩因特大卫·佩里曼格雷戈里·R·布鲁姆林
Owner EMORY UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com